APC Genotype

If colon cancer or a diagnosis of many colon polyps shows up in your family, a single gene explains a large share of the inherited cases. Knowing whether you carry a faulty copy can change when you start colonoscopies, whether you consider preventive surgery, and what you tell your children.

This test reads the gene directly rather than waiting for polyps to appear. A harmful change here can mean a lifetime of managing hundreds of growths, or a milder inherited pattern that still deserves earlier and more frequent screening than the general public gets.

What This Gene Does

The APC (adenomatous polyposis coli) gene acts as a brake on cell growth in the lining of your intestine. It works largely by keeping a growth-signaling protein called beta-catenin from building up inside cells, which is how it limits runaway multiplication of the cells that renew your gut lining.

When both copies of the gene lose function, that brake fails. Cells in the colon lining multiply faster, organize poorly, and accumulate further genetic errors, which is the starting point for polyps and, over time, cancer. Most harmful inherited changes in this gene are the kind that cut the protein short and strip away the parts that do this job.

Familial Adenomatous Polyposis

The most established use of this test is diagnosing familial adenomatous polyposis, usually shortened to FAP. In the classic form, the colon develops hundreds to thousands of polyps, and without treatment the lifetime risk of colon cancer approaches certainty.

Classic, severe polyposis is linked to changes in the broad central stretch of the gene. Changes at codon 1309 in particular are tied to unusually dense polyps, earlier cancer, and a poor chance of keeping the rectum after surgery. A faulty copy is inherited in a dominant pattern, meaning a parent with it has roughly a one-in-two chance of passing it to each child. About a third of cases arise instead from a new mutation with no prior family history, so a clean family tree does not rule FAP out.

The Attenuated Form

Not everyone with a harmful change in this gene develops the classic picture. An attenuated form typically produces fewer than 100 polyps and pushes the age of colon cancer later, with the average diagnosis after 50, though the lifetime risk still approaches 70% if the polyposis is left untreated. This milder pattern is enriched for changes near the front end of the gene, in the alternatively spliced region of exon 9, and at the far tail end.

This matters because attenuated disease can look, on the surface, like ordinary late-onset colon cancer with a scattering of polyps. Without genetic testing, the inherited cause can be missed for years, and relatives who would benefit from earlier screening never learn they are at risk.

Disease Beyond the Colon

Harmful changes in this gene do not stop at the colon, and where the change sits in the gene shifts which other problems are likely. The clearest links are to growths in the small intestine and to desmoid tumors, which are aggressive but non-spreading masses of fibrous tissue.

• Desmoid tumors: changes in the region spanning codons 1310 to 2011 carried about six times the desmoid risk of the lowest-risk part of the gene in one large series of families, though other studies report different magnitudes depending on where the cutoff is drawn, so treat the exact figure as one estimate among several.
• Duodenal growths: changes at codons 976 to 1067 are tied to roughly three to four times the risk of adenomas in the first part of the small intestine, although upper gut correlations are less consistent across studies.
• Eye and thyroid findings: changes between codons 543 and 1309 track with a harmless retinal pigment change used as a marker, and FAP-linked thyroid cancer clusters in a defined stretch of the gene rather than the classic severe-polyposis zone.
• Childhood tumors: carriers face a small increased risk of hepatoblastoma, a liver tumor of early childhood at roughly 0.4 to 2.5% and typically appearing before age three, and medulloblastoma, a brain tumor at about 1%, both of which inform pediatric screening decisions in affected families.

A newer study of an aggressive subgroup found that changes in codons 1398 to 1580 came with strikingly high rates of severe outside-the-colon disease, including advanced-stage desmoids, dense stomach polyps, and severe small-intestine involvement. For carriers in these regions, more intensive surveillance of the stomach and small bowel is reasonable.

The I1307K Variant and Ashkenazi Jewish Ancestry

One specific change in this gene, called I1307K, is a different story from the FAP-causing changes. It does not cause polyposis. Instead it is a low-penetrance risk change, meaning it modestly raises colon cancer risk rather than nearly guaranteeing it.

The evidence for I1307K is strongest in people of Ashkenazi Jewish descent, where estimates of how often it appears range from about 6 to 7 percent of unselected individuals, and it has been tied to roughly 1.7 to 1.8 times the colon cancer risk of non-carriers. The international expert position is to classify it as a genuine but low-penetrance risk change in that population, and not as evidence of risk in other ancestries.

A large prospective study of 466,315 UK Biobank participants, including 8,944 colon cancer cases, found no statistically significant link between I1307K and colon cancer in either the Ashkenazi Jewish group (about 0.7 times the odds, a wide range from 0.17 to 2.95) or non-Ashkenazi white participants. The authors were clear this study was underpowered in Ashkenazi cases, so it does not overturn the earlier modest risk estimate, but it does argue against treating I1307K as a high-risk finding.

Why Location Only Partly Predicts Your Future

It is tempting to read this gene like a dial, where a specific change automatically sets a specific severity. The evidence says otherwise. Where the change sits predicts broad patterns, such as attenuated versus classic disease, or higher desmoid risk, but substantial differences remain even among relatives who carry the exact same change. This is not a contradiction to resolve so much as a reminder of what the test is: a risk-stratification tool, not a fixed script. It reliably separates milder from severe inherited patterns and flags regions tied to specific complications, while the precise number of polyps, the age of onset, and which complications actually appear still vary from person to person. That is why a positive result guides monitoring and prevention rather than dictating a single predetermined outcome.

A One-Time Test You Act On for Life

Your genotype does not change, so this is a once-in-a-lifetime test. There is no trend to track and no reason to repeat it unless a different, more sensitive method is needed to confirm or clarify an uncertain result.

The value comes from what you do with the answer over the following decades, not from retesting the gene. If you carry a harmful change, the tracking shifts to your colon and other at-risk organs: colonoscopy on a schedule set by your genotype and phenotype, plus surveillance of the stomach and small intestine for carriers in the higher-risk regions. In one Japanese cohort, different genotype groups reached the age when advanced colon cancer risk rose at markedly different points, roughly 34 versus 49 years, though the authors stressed this is not yet solid enough to set surgery timing without more study.

What to Do With an Unexpected Result

A positive result should trigger a workup, not panic. The first steps are confirming the finding, involving a genetics professional, and starting or intensifying colonoscopy. A positive result also opens cascade testing, where first-degree relatives can be tested for the same specific change so those who carry it get early screening and those who do not are spared it.

A negative result on a standard blood test is not always the end of the question. When someone clearly has polyposis but standard sequencing finds nothing, broader methods matter. Multigene panels can find changes in other polyposis genes such as MUTYH (a gene where two faulty copies cause a recessively inherited polyposis). Deeper testing can uncover large deletions, mosaicism, and splice-altering changes that routine sequencing misses. In one series of unexplained classic polyposis, whole-gene deletions accounted for 12% of cases, and testing polyp tissue itself has revealed changes confined to the colon that never show up in blood. If your phenotype is convincing but your first test is negative, that is a reason to push for a specialist and additional methods, not to assume you are in the clear.

When a Result Can Mislead You

Genetic results carry their own traps that differ from ordinary blood tests. The most important is understanding what a negative actually rules out and what it does not.

• What the assay covers: a test only detects the changes it is designed to find. Standard sequencing can miss large deletions and duplications, mosaicism, and deep intronic or splice-region changes, so a negative does not fully exclude inherited risk when polyposis is present.
• Ancestry changes the meaning: the I1307K change is a meaningful risk factor in Ashkenazi Jewish individuals but has not been shown to raise risk in other populations, so the same result can mean different things depending on your background.
• Uncertain variants: a change of unknown significance may be reported, meaning the lab found something but cannot yet say whether it affects health, which is not the same as a confirmed harmful result.
• Mosaicism in tissue only: some harmful changes are present in colon tissue but not detectable in blood, so a clean blood test in someone with clear polyposis may warrant testing the affected tissue directly.

Result interpretation errors are common even among clinicians. In one nationwide analysis from the late 1990s, physicians misinterpreted APC test results in 31.6% of cases. That study predates today's genetic counseling infrastructure, so current rates may differ, but it remains a strong argument for having a genetics professional read your result in context.